Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05274204 | Individual Patient Expanded Access to CA102N | no longer available | — | — | Holy Stone Healthcare Co., LtdINDUSTRY | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07083479 | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma(AMPLIFY-EAP) | no longer available | — | — | Elicio TherapeuticsINDUSTRY | 0 | Jul 10, 2026 |
| clinicaltrials |
| NCT07399015 | Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC | no longer available | — | — | Endevica BioINDUSTRY | 0 | Feb 18, 2026 | clinicaltrials |
| NCT06195514 | Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC) | no longer available | — | — | TakedaINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT03756311 | Expanded Access to NanoPac | no longer available | — | — | NanOlogy, LLCINDUSTRY | 0 | Jan 23, 2026 | clinicaltrials |
| NCT04087889 | Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer | no longer available | — | — | Hope Biosciences LLCINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04681248 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | no longer available | — | — | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT04087876 | Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | no longer available | — | — | Basilea PharmaceuticaINDUSTRY | 0 | Apr 6, 2025 | clinicaltrials |
| NCT03414489 | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | no longer available | — | — | RedHill Biopharma LimitedINDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05683548 | Replicor Compassionate Access Program(RCAP) | no longer available | — | — | Replicor Inc.INDUSTRY | 5 | Feb 17, 2025 | clinicaltrials |
| NCT04446793 | Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | no longer available | — | — | Cardiff OncologyINDUSTRY | 0 | Feb 12, 2024 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02960620 | Therasphere for Unresectable Primary or Secondary Liver Neoplasia | no longer available | — | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02449135 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma | no longer available | — | — | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04137822 | Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer | no longer available | — | — | Impatients N.V. trading as myTomorrowsINDUSTRY | 2 | Aug 14, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT01538680 | Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy(CONSIGN) | no longer available | — | — | BayerINDUSTRY | 25 | May 29, 2019 | clinicaltrials |
| NCT02564224 | Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients(PURSE) | no longer available | — | — | Zhejiang UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00701168 | Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer | no longer available | — | — | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT00589030 | Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | no longer available | — | — | City of Hope Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02082691 | Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma | no longer available | — | — | Devalingam MahalingamOTHER | 0 | Mar 10, 2014 | clinicaltrials |
| NCT01728051 | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | no longer available | — | — | Delcath Systems Inc.INDUSTRY | 1 | Oct 23, 2013 | clinicaltrials |
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials